Agios Pharmaceuticals (NASDAQ:AGIO) Shares Break Below 200 Day Moving Average – Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $31.70 and traded as low as $29.80. Agios Pharmaceuticals shares last traded at $30.55, with a volume of 3,094,276 shares changing hands.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said updated safety data showed no new cases of hepatocellular injury in sickle cell patients treated with mitapivat. The company remains confident in the drug’s benefit-risk profile, is launch-ready, and continues labeling discussions with the FDA. Agios FDA review update
• Positive Sentiment: An analyst view argued that the delay may not invalidate the bullish thesis because mitapivat demonstrated meaningful reductions in transfusion burden, despite mixed efficacy on pain-crisis endpoints. Seeking Alpha upgraded the stock, while HC Wainwright maintained a “buy” rating with a $55 price target. Agios sickle cell analysis
• Neutral Sentiment: Agios was expected to potentially beat estimates in its upcoming quarterly report, but the earnings preview provided no confirmed results or new operating data. Agios earnings preview
• Negative Sentiment: The FDA extended the PDUFA decision date for mitapivat’s sickle cell supplemental application by three months, from November 1, 2026, to February 1, 2027. The extension followed the agency’s request for additional information on whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. The FDA classified Agios’ response as a major amendment, delaying a potential approval and launch timeline. Agios shares fall on FDA review extension
• Negative Sentiment: The REMS review raises concerns about possible safety-related prescribing restrictions and commercialization requirements. In addition, mitapivat did not meet the sickle-cell pain-crisis endpoint, increasing uncertainty around the breadth of its eventual label.
• Negative Sentiment: A recent pre-arranged sale by Chief Medical Officer Sarah Gheuens adds a modest negative sentiment signal, although the transaction was not identified as the primary reason for the selloff. Agios insider sale

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $55.00 target price on the stock. Royal Bank Of Canada increased their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. raised their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Agios Pharmaceuticals Stock Down 17.9%

The business has a 50-day simple moving average of $33.62 and a two-hundred day simple moving average of $31.70. The stock has a market capitalization of $1.82 billion, a P/E ratio of -4.36 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. On average, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -5.81 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 39,855 shares of company stock valued at $1,285,512. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $239,582,000. Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after acquiring an additional 1,782,457 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $47,800,000. Dimensional Fund Advisors LP grew its position in Agios Pharmaceuticals by 14.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after acquiring an additional 147,273 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $24,828,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.